Last reviewed · How we verify
NCT06270771: OURA MDS
OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
trial testing OURA Ring in MDS in 60 participants. Currently enrolling.
20 March 2026
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 20 March 2025 |
| Primary completion | 20 March 2026 |
| Estimated completion | 1 February 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- OURA Ring
Conditions studied
- MDS — all drugs for MDS →
- Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
- Myelodysplastic/Myeloproliferative Neoplasms — all drugs for Myelodysplastic/Myeloproliferative Neoplasms →
- RARS-T — all drugs for RARS-T →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
18 and older, any sex, with MDS or Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, single center, single arm phase 2 cohort feasibility study of the OURA ring in adult MDS patients. Patients with MDS will wear the OURA ring and upload biometrics weekly. Quality of life measures will be clinically evaluated and correlated with biometrics. We hypothesize that it will be feasible for MDS patients to wear the OURA ring 70% of the time for 3 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06270771
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of OURA Ring
Trials testing the same drug.
- NCT05099237 — Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester · NA · unknown
Other recruiting trials for MDS
Currently open trials in the same condition.
- NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
- NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
- NCT06972641 — Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 2, PHASE3 · recruiting
- NCT07006025 — A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) · Phase 1 · recruiting
- NCT06895538 — Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy · recruiting
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06270771 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06270771.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing